90 years of changing diabetes.

Madrid, 2013 February- Novo Nordisk celebrates 90 years and celebrated in 1923 it was the first patient with insulin made by the Danish company.

since then, Novo Nordisk has focused on the development of new and better treatments for people with diabetes and is today the leading company in the care of diabetes around the world. Novo Nordisk provides therapeutic treatments to more than 23 million people around the world and produces 50% of insulin that is consumed world-wide.

In Spain, the company has been working to change the diabetes since 1974.

The beginnings of Novo Nordisk

In 1922, during a visit to the United States, August Krogh, Danish Nobel Prize, and his wife, Marie, a doctor with diabetes, knew the discovery of insulin in Canada. Marie encouraged August to meet with Professor Macleod in Toronto, since he had been the leader of the team of researchers behind this discovery. August and Marie returned to Copenhagen in December 1922, and brought with them an authorization and the desire to begin with the production of insulin in Scandinavia. A few months later, they had already begun to produce insulin and the first patients began to be treated in a Danish hospital. That was the beginning of what is now Novo Nordisk.

Since then, the company has pioneered many of the most important advances made in the treatment of diabetes, which include human insulin (1982) and the first developed in the world, NovoPen ® (1985) insulin Pen. Later, Novo Nordisk developed different modern insulins (enhanced insulin analogues) and now leads a new class of diabetes treatments – therapies of GLP-1. In parallel, Novo Nordisk has applied his knowledge and know how ” in the field of diabetes to the development of other Biopharmaceuticals for the treatment of Hemophilia and growth disorders.

Novo Nordisk is the majority shareholder of the Novo Nordisk Foundation, a Danish Foundation which provides a stable base for the company’s commercial activity and supports humanitarian and scientific purposes the same.

In 2002, Novo Nordisk founded the World Diabetes Foundation, which has grown to become the leading international foundation in material of diabetes and supports all initiatives aimed at the prevention and treatment of this disease in developing countries.

The Novo Nordisk Haemophilia Foundation was created in 2005 with the vision that all persons with hemophilia or other clotting disorders should receive adequate treatment regardless of the place in which to live.

About Novo Nordisk

With headquarters in Denmark, Novo Nordisk is a global company dedicated to the health care with 90 years of innovation and leadership in diabetes care. The company holds a leading position within areas such as hemostasis control, growth hormone therapy and hormone replacement therapy.